So has pharma run out of ideas in diabetes? Not exactly. But whether its ideas will ever get to market is another question. There’s plenty of promising science in the early stages of research. Available drugs, however, work pretty well. Given the cost of development and a high bar for approval, pharma can only afford […]
A study in Diabetes Care showed that patients with poorly controlled type 2 diabetes who received a combination of exenatide and pioglitazone had a threefold lower rate of hypoglycemia, a one-percentage-point greater reduction in A1C and less weight gain than those in the basal-bolus insulin therapy group.
Both products, known as LixiLan and IDegLira during clinical trials, were delayed by 3 months at the U.S. Food and Drug Administration (FDA) following recommendations for approval from FDA panels back in May. And yet the FDA has approved the two new competing combination products containing fixed doses of glucagonlike-peptide 1 (GLP-1) receptor agonists and […]
The US Food and Drug Administration (FDA) has approved the slow release form of Synjardy. Synjardy is a drug used by people with type 2 diabetes in the UK as a twice daily single pill combination therapy to lower blood sugar levels.
If you’re like nearly one-third of Americans over age 40, you probably take a statin. These cholesterol-lowering drugs are used for reducing risk of stroke and heart attack. They work by lowering the amount of LDL cholesterol, the so-called “bad cholesterol” in the blood. Statins also reduce inflammation around plaque in the blood vessels.
The researchers found that the risk of cancers of the colon (males only), liver (males only), pancreas, lung (males only), and brain (males only) were increased up to nine-fold for patients treated with insulin or insulin secretagogues; the risk of prostate cancer was decreased strongly. The risks were generally decreased for patients taking statins, with […]
The type 2 diabetes drug liraglutide could affect heart variability in newly diagnosed people who are overweight and have heart problems, according to new research. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which helps control blood sugar levels and reduces post-meal hyperglycemia. The drug is marketed as Victoza and Saxenda.
Believe it or not, some people were disappointed and underwhelmed by solid evidence that Victoza (ligratude), a medication for type 2 diabetes, reduces the risk of fatal diabetes complications. That news, based on a massive clinical trial of Novo Nordisk’s drug, was one of the mostly widely reported items from the American Diabetes Association’s recent […]
A novel treatment meant to stop Type 1 diabetes by increasing the number of T cells in the body is being given special attention by the FDA. The treatment, called CLBS03, has recently been granted Fast Track status by federal regulators, a designation which speeds up the approval process.
New research suggests that taking painkillers known as non-steroidal anti-inflammatory drugs (NSAIDs) – which includes ibuprofen – increases the risk of heart failure by less than 20% overall. NSAIDs are a group of painkilling medicines commonly taken by people with joint problems, backache and arthritis. They are prescribed to relieve pain and reduce inflammation.
Many people with type 2 diabetes take the drug metformin to control their blood sugar levels. But now, new research suggests that his drug may also benefit type 1 diabetics, by slowing down the progression of heart disease.
Research published Wednesday found that states that legalized medical marijuana — which is sometimes recommended for symptoms like chronic pain, anxiety or depression — saw declines in the number of Medicare prescriptions for drugs used to treat those conditions and a dip in spending by Medicare Part D, which covers the cost on prescription medications.
Over a one-year study, glycemic control was improved and body weight and blood pressure were reduced with Invokana® (canagliflozin, Janssen) as add-on therapy to metformin in patients with type 2 diabetes, according to a presentation at AACE.
GLP-1 Victoza reduces the risk of death from heart disease, kidney disease, hypoglycemia, severe hypoglycemia, and other complications in people with type 2 diabetes at high risk for heart disease.
Pharma companies are testing whether drugs designed for combatting Type 2 diabetes can be used to also treat Type 1 diabetes. The latest attempt involves a class of of oral antidiabetics called SGLT2 inhibitors, first cleared by the Food and Drug Administration on March 29, 2013.
Type 2 diabetic patients who took both insulin and metformin showed a reduced risk of death and cardiac events compared with people treated with insulin alone, according to a new study conducted by researchers at Cardiff University.
Last November, JDRF officials announced that researchers had found biological markers for Type 1 diabetes long before symptoms appeared in children. Now another group of researchers hope to see if they can prevent Type 1 before children become symptomatic, and to do it they are planning to use a classic tool in diabetes management – […]
It was supposed to be a great marriage of a new product and deep pockets. In 2014, the pharmaceutical giant Sanofi agreed to market Afrezza, an inhalable insulin created by Mannkind Corporation. It didn’t work out that way.
The FDA recently released a Drug Safety Communication announcing revisions to metformin’s label to expand use in people with type 2 diabetes and mild to moderate kidney (renal) impairment. Previously, the FDA advised against using metformin (Glucophage, Glumetza, Riomet, and Fortamet) in this group.
Earlier this month, at the Endocrine Society’s annual conference in Boston, Danish pharma Novo Nordisk presented three years of data showing that their diabetes drug liraglutide helped obese and prediabetic patients lose weight without undue risk. Which is big, for a drug that’s been flagged for causing cancer.